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Abstract:
Objective: Role of reactive oxygen species (ROS) modified human Immunoglobulin G (IgG) in systemic lupus erythematosus (SLE) 
has been investigated.
Methods: Human IgG was modified by hydroxyl-radicals. Immunogenicity of native and modified human IgG was probed by inducing 
polyclonal antibodies in rabbits. Cross-reactions of induced antibodies with nucleic acid, chromatin, different blood proteins and their 
ROS modified conformers were determined by competitive inhibition ELISA. The binding characteristics of circulating autoantibodies 
in SLE patients (n = 72) against native and modified IgG were screened by direct binding and competition ELISA and the results were 
compared with healthy age-matched controls (n = 39).
Results: Induced antibodies against ROS-modified human IgG exhibited diverse antigen binding characteristics. Native DNA, native 
chromatin and their ROS-modified conformers were found to be effective inhibitors of induced antibody-immunogen interaction. 
Induced antibodies against native human IgG showed negligible binding to the above mentioned nucleic acid antigens. SLE sera 
(48.6%) showed strong binding to ROS-human IgG in comparison with its native analogue (P , 0.01). Normal human sera (NHS) 
showed negligible binding with either antigen (P . 0.05).
Conclusion: ROS-induced modifications in human IgG present neo-epitopes, and make it a potential immunogen. The induced anti-
bodies against ROS-modified human IgG resembled the diverse antigen-binding characteristics of naturally occurring SLE anti-DNA 
autoantibodies. ROS-modified IgG may be one of the factors for the induction of circulating SLE autoantibodies.
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Introduction
Systemic lupus erythematosus (SLE) is a multifac-
torial autoimmune disease characterized by several 
clinical manifestations and the appearance of multi-
ple autoantibodies.1–4 Analysis of sera obtained from 
the same SLE patient over a long period of time has 
demonstrated  that  different  autoantibody  specifici-
ties appear at different time intervals with a general 
trend towards increasing the number of antigens rec-
ognized by the sera.3 These observations of increas-
ing complexity of this autoimmune response over a 
period of time are very similar to those reported by 
Lehmann et al.4 in their mode of epitope spreading in 
experimental autoimmune encephalomyelitis. Thus, 
it was generally accepted that intermolecular epitope 
spreading was one of the mechanisms for the ampli-
fication and diversification of autoantibody responses 
in SLE.5,6 In short, SLE is a multisystem autoimmune 
disorder of unknown etiology6 or the agent (or agents) 
triggering this autoimmune response remains to be 
identified,  but  it  is  thought  that  a  combination  of 
genetic and environmental factors are required.6–8
Reactive  oxygen  species  (ROS)  has  the  poten-
tial to initiate damage to proteins, DNA and other 
cell  biomolecules  under  pathological  conditions.9 
  Protein oxidation, which results in functional disrup-
tion, is not random but appears to be associated with 
increased oxidation in specific proteins.10–14 We previ-
ously reported that many serum proteins were found 
to be oxidatively modified leading to the formation of 
neoantigens which could in turn initiate autoimmunity 
in  various  diseases15–20  including  SLE.21  Oxidative 
stress and formation of oxidatively-modified protein 
are associated with SLE,8,21,22 however, the potential 
role of oxidative stress, especially the consequences 
of oxidative modification of proteins, in the patho-
genesis and progression of SLE remains unresolved.
Immunoglobulin  G  (IgG)  is  the  most  abundant 
immunoglobulin and is approximately equally dis-
tributed in blood and in tissue liquids, constituting 
75%  of  serum  immunoglobulins  in  human.  Func-
tion of IgG lies in the specific interactions with and 
clearance of antigen. It is well known that IgG is 
quite vulnerable to ROS.23–29 Many studies showed 
the presence of elevated levels of oxidized IgG in 
patients with rheumatic diseases.26–28 In patients with 
SLE, IgG dysfunction has been reported.26 Now, it 
is well documented that IgG behaves not only as an 
antibody, but also as a putative antigen for rheumatoid 
factor.20,26 Therefore, IgG is continuously exposed to 
oxidative stress, as the alterations in its conformation 
and function could occur, resulting in modification of 
its biological properties.
In the present study, we demonstrated that after 
modification with ROS, human IgG became highly 
immunogenic in experimental animals and the induced 
antibodies against ROS-modified IgG showed cross-
reactions with native and ROS-modified nucleic acid 
conformers. Therefore, we hypothesized that oxida-
tive by-products, such as hydroxyl radicals-damaged 
human IgG, help to initiate autoimmunity in SLE. 
To test this hypothesis, we investigated the binding 
characteristics of naturally occurring SLE autoanti-
bodies to native and hydroxyl radical-modified IgG.
Methods
Purification of human immunoglobulin G, 
human DnA and chromatin
IgG from normal human sera was purified using Protein 
A-Sepharose CL-4B affinity column (Sigma-  Aldrich 
St. Louis, MO, USA) as previously described.20 Briefly, 
serum diluted with equal volume of PBS, pH 7.4 and 
applied  to  the  column  equilibrated  with  the  same 
  buffer. The flow through was reloaded onto the column 
2–3 times. Unbound proteins were removed by exten-
sive washing with PBS, pH 7.4. The bound IgG was 
eluted with 0.58% acetic acid in 0.85% sodium chlo-
ride and neutralized with 1.0 ml of 1.0 mol/l Tris HCl, 
pH 8.5. The purified IgG was dialyzed against PBS, 
pH 7.4 and stored at −20 °C. Concentration of IgG 
was determined using 1.38 OD278 = 1.0 mg IgG/ml. 
The  homogeneity  of  isolated  IgG  was  checked  by 
polyacrylamide gel electrophoresis.
Human DNA was purified from the blood of healthy 
human subjects, which was free of protein, RNA and 
single-stranded  regions  as  previously  described.30 
Chromatin was purified from goat liver as described 
previously.31
ROS-modification of human IgG, HSA, 
human hemoglobin, human transferring, 
human DnA and chromatin
Human  IgG,  HSA  (Sigma-Aldrich  Co.),  human 
hemoglobin (Sigma-Aldrich Co.), human transferring rOS-Igg in SLe
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(Sigma-Aldrich Co.), human DNA and chromatin was 
modified in PBS (10 mM sodium phosphate buffer 
containing 150 mM NaCl, pH 7.4) by our published 
procedure.18 Proteins or nucleic acid conformers were 
modified by hydroxyl radicals, generated with UV 
irradiation (30 min) of hydrogen peroxide (15.1 mM) 
at 254 nm. Unbound hydrogen peroxide was removed 
by extensive dialysis against PBS, pH 7.4.
Preparation of advanced gylcation  
end products (Ages)
AGEs was prepared by independent reactions of dif-
ferent  plasma  proteins  (HSA,  human  IgG,  human 
transferrin,  or  hemoglobin)  with  glycoaldehyde 
(Sigma-Aldrich,  Co.)  according  to  our  published 
procedure.32–34 The reaction was terminated by remov-
ing non-reacted glycoaldehyde using dialyzing exten-
sively against PBS, pH 7.2.
Immunization schedule
The  immunization  of  random  bred,  female  New 
Zealand white rabbits was performed as described 
previously18,20 Briefly, rabbits (n = 4; two each for 
native and ROS-human IgG antigens) were immu-
nized intramuscularly at multiple sites with 25 µg 
of  antigen,  emulsified  with  an  equal  volume  of 
  Freund’s  complete  adjuvant  (Sigma-Aldrich,  Co.). 
The  animals  were  boosted  in  Freund’s  incomplete 
adjuvant   (Sigma-Aldrich, Co.) at weekly intervals for 
6 weeks with the same amount of antigen. Test bleeds 
were performed 7 days post boost, which gave appro-
priate titer of the antibody. The animals were bled and 
the serum separated from the blood (pre-immune and 
immune) was heated at 56 °C for 30 min to inactivate 
complement proteins and stored at −80 °C.
human subjects
The study group included 72 patients (63 females and 
9 males; aged (±SD) 43.6 ± 13.3 years) with SLE, as 
defined by the American College of   Rheumatology 
1997 revised criteria34 and the age range was 29–69 
years (43.6 ± 13.3 years). The control group comprised 
39 healthy volunteers (36 females and 3 males; aged 
(±SD) 45.7 ± 13.8 years). The study was approved by 
Qassim University Medical Review Board. Venous 
blood samples from the control subjects and from 
SLE patients were collected and serum was separated. 
Full informed consent was obtained prior to the blood 
extraction from SLE patients and healthy subjects. 
All serum samples were decomplemented at 56 °C 
for 30 min and stored in small   aliquots at −80 °C.
Assay of carbonyl formation
Protein carbonyl contents in SLE patients sera and 
in healthy human sera were analyzed as described 
previously35 with slight modifications. The reaction 
mixture containing 0.5 ml of 10 mM 2,4-dinitrophe-
nylhydrazine (DNPH)/2.5 MHCl and 1:100 diluted 
sera from study subjects and was thoroughly mixed. 
After addition of 250 mM TCA (20%) and centrif-
ugation, the pellet was collected and washed three 
times with 1 ml ethanol:ethylacetate (1:1) mixture. 
The pellet was then dissolved in 1 ml of 6 M guani-
dine solution and incubated at 30 °C for 15 min. 
After centrifugation, the supernatant was collected 
and carbonyl contents were estimated using molar 
absorption coefficient of 22,000 M−1 cm1. Samples 
were  spectrophotometrically  analyzed  against  a 
blank of 1 ml of guanidine solution (6M). Protein 
concentration was determined in the samples by the 
method of Lowry et al.36
enzyme linked immunosorbent  
assay (eLISA)
Antibodies against native and ROS-modified human 
IgG  were  detected  and  quantified  using  ELISA 
assays performed on flat bottom 96 wells, polysty-
rene immunoplates as previously described.15,16 Poly-
styrene  polysorp/maxisorp  immunoplates  (Thermo 
Fisher Scientific, Fremont, CA, USA) were coated 
with 100 ml of native or modified IgG (5 µg/ml) or 
DNA  (2.5  µg/ml)  in  carbonate–bicarbonate  buffer 
(0.05 M, pH 9.6). The plates were coated for 2 h at 
37 °C and overnight at 4 °C. Each sample was coated 
in duplicate and half of the plates served as control 
devoid of only antigen coating. Unbound antigen was 
washed thrice with TBS-T (20 mM Tris, 150 mM, 
NaCl, pH 7.4 containing 0.05% Tween-20) and unoc-
cupied sites were blocked with 2% fat free milk in 
TBS (10 mM Tris, 150 mM NaCl, pH 7.4) for 4–6 h 
at 37 °C. After incubation the plates were washed four 
times with TBS-T. The test serum serially diluted in 
TBS-T in TBS (100 ml/well) was adsorbed for 2 h at 
37 °C and overnight at 4 °C. Bound antibodies were Al-Shobaili et al
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assayed with human alkaline phosphatase   conjugate 
using p-  nitrophenyl phosphate as substrate. The absor-
bance (A) of each well was monitored at 410 nm on 
an automatic microplate reader. Each sample was run 
in duplicate. The control wells were treated similarly 
but were devoid of antigen. Results were expressed as 
a mean of Atest—Acontrol.
Competition eLISA
The antigenic specificity of the antibodies was deter-
mined by competition ELISA.17,18 Varying amounts of 
inhibitors (0–20 mg/ml) were mixed with a constant 
amount of serum samples. The mixture was incubated 
at room temperature for 2 h and overnight at 4 °C. 
The immune complex thus formed was coated in the 
wells instead of the serum. The remaining steps were 
the same as in direct binding ELISA. Percent inhibi-
tion was calculated using the formula:
Percent inhibition = [1 − (Ainhibition/Auninhibition)] × 100
Statistical analysis
All measurements were performed in duplicates and 
repeated at least 3 times using age- and sex-matched 
SLE or control samples. Comparisons were performed 
using  Origin  6.1  software  package  (Northampton, 
MA,  USA)  (one  paired  two  tailed  t-test  with  one 
way ANOVA analysis). P values less than 0.05 were 
considered significant, and P values less than 0.001 
were considered highly significant. Values shown are 
mean ± SEM unless stated otherwise.
Results
Human IgG was purified from normal human sera by 
affinity  chromatography  using  Protein-A    Sepharose 
CL-4B affinity column. The purified IgG was found 
to elute as a single symmetrical peak and gave a sin-
gle band on SDS-PAGE (data not shown). Our earlier 
report20 showed alterations in human IgG following 
exposure to the hydroxyl radicals, generated by the 
UV-irradiation  of  hydrogen  peroxide.  Loss  of  sec-
ondary structures, hypochromicity at 280 nm, loss of 
tryptophan fluorescence intensity, increase in protein 
carbonyl contents were observed in hydroxyl treated 
human IgG. We also showed previously that immuni-
zation of ROS-modified human IgG in rabbits induced 
high titre antibodies (.1:12,800), whereas with native 
human IgG the titre was low (∼1:6400).20 In the   present 
study, we studied the   antigenic   specificity of the exper-
imentally induced antibodies against native and ROS-
modified human IgG by competitive inhibition assay. 
A maximum of 97% inhibition of the affinity purified 
anti-ROS-human  IgG  antibodies  with  the  immuno-
gen as inhibitor, was observed (Table 1). Competition 
experiments with native human IgG used as inhibi-
tor showed 51.2% inhibition at 20 µg/ml. The affinity 
purified anti-ROS-human IgG antibodies exhibited a 
variable recognition of chromatin, DNA, ROS-mod-
ified-chromatin  and  ROS-modified  DNA  (Table  1). 
Native chromatin and native DNA showed maximum 
inhibition  of  48.2%  and  56.3%,  respectively,  and 
18.2 µg/ml of native DNA was required for 50% inhi-
bition, whereas the ROS-modified conformers of chro-
matin and DNA showed maximum inhibition of 63.2% 
and 65.4%, respectively at 20 µg/ml of inhibitor con-
centration. 50% inhibition of anti-ROS-IgG antibodies 
was achieved at 7.4 and 10.2 µg/ml of ROS-modified 
DNA  and  ROS-modified  chromatin,  respectively. 
Percentage of relative affinity of anti-ROS-IgG anti-
bodies in respect with inhibitors was also estimated 
which  further  confirmed  that  anti-ROS-human  IgG 
antibodies exhibited diverse antigen binding charac-
teristic  with  native  and  ROS-modified  nucleic  acid 
conformers (Table 1). Glycated IgG showed negligible 
inhibitions of 16.5%, whereas native HSA and gly-
cated HSA showed inhibition of 18.0% and 14.1%, 
respectively. Native human hemoglobin and glycated 
hemoglobin showed inhibition of 11.0% and 17.0%, 
respectively,  whereas  ROS-modified  conformers  of 
HSA  and  hemoglobin  showed  moderate  inhibition 
of 28.0% and 27.0%, respectively. Transferrin, ROS-
modified transferrin was non-inhibitory. The complete 
antigen  binding  specificity  of  affinity  purified  anti-
ROS-human  IgG  antibodies  has  been  summarized 
in Table 1. Competitive inhibition ELISA results of 
antigen binding characteristics of affinity purified anti-
human IgG antibodies were shown in Table 2. Our 
data with anti-native human IgG antibodies showed a 
maximum inhibition of 89.0% with the immunogen as 
inhibitor. Only 9.7 µg/ml of native IgG was required to 
inhibit 50% its activity. The induced antibodies partially 
recognized ROS-modified human IgG as it showed a 
maximum inhibition of 56.1%. Inhibitor 17.2 µg/ml 
was required to inhibit 50% antibody binding activ-
ity to native IgG. Native chromatin and native DNA 
showed  maximum  inhibition  of  32.2%  and  22.2%, rOS-Igg in SLe
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Table 2. Antigen binding specificity of anti-human IgG antibodies.
Inhibitors Maximun % inhibition 
at 20 μg/ml
Concentration for 50% 
inhibition (μg/ml)
% relative 
affinity
native-Igg 89.0 ± 2.1 9.71 ± 2.3 100
rOS-Igg 56.1 ± 3.5 17.2 ± 1.4 56.4
Chromatin 32.2 ± 4.1 – –
rOS-chromatin 41.1 ± 1.1 – –
human DnA 22.2 ± 3.5 – –
rOS-human DnA 34.1 ± 2.1 – –
Age-Igg 13.2 ± 1.5 – –
native hSA 10.7 ± 4.2 – –
Age-hSA  11.2 ± 2.1 – –
rOS-hSA 19.6 ± 2.8 – –
hemoglobin 13.0 ± 1.1 – –
rOS-hemoglobin 13.3 ± 2.5 – –
Age-hemoglobin 11.0 ± 1.4 – –
Transferrin 10.2 ± 2.7 – –
rOS-transferrin 12.5 ± 3.1 – –
Notes: The results represent mean ± SD of four independent assays. The eLISA plates were coated with native-Igg (10 mg/ml).
Table 1. Antigen binding specificity of anti-ROS-modified human IgG antibodies.
Inhibitors Maximun % inhibition 
at 20 μg/ml
Concentration for 50% 
inhibition (μg/ml)
% relative 
affinity
rOS-Igg 96.8 ± 3.2 0.83 ± 1.3 100
native Igg 51.2 ± 4.3 19.1 ± 2.6 4.3
Chromatin 48.2 ± 2.2 – –
rOS-chromatin 63.2 ± 2.7 10.2 ± 3.1 8.1
human DnA 56.3 ± 4.2 18.2 ± 2.1 4.5
rOS-human DnA 65.3 ± 3.3 7.2 ± 2.3 11.5
Age-Igg 26.5 ± 2.4 – –
native hSA 18.0 ± 4.4 – –
Age-hSA 14.1 ± 5.3 – –
rOS-hSA 28.0 ± 3.2 – –
hemoglobin 11.0 ± 3.2 – –
Age-hemoglobin 19.0 ± 4.2 – –
rOS-hemoglobin 27.0 ± 2.1 – –
Transferrin 09.6 ± 3.2 – –
rOS-transferrin 10.2 ± 2.5 – –
Notes: The results represent mean ± SD of four independent assays. The eLISA plates were coated with rOS-Igg (10 mg/ml).
respectively, whereas ROS-chromatin and ROS-DNA 
showed  maximum  inhibition  of  41.1%  and  34.1%, 
respectively (Table 2).
To probe the possible role of the ROS in the patho-
genesis of SLE, 72 SLE sera were selected for bind-
ing to native and ROS-modified human IgG. Majority 
of  SLE  sera  (35/72)  showed  strong  binding  to 
ROS-modified IgG over native IgG (P , 0.01) (Fig. 1). 
Normal human sera (NHS) showed negligible binding 
with native or modified IgG (P . 0.05). Native DNA 
was used as an immunochemical marker for SLE, 
showed  strong  binding  to  SLE  serum  antibodies; 
whereas  antibodies  from  NHS  showed  negligible 
binding to native DNA (Fig. 1). The average absor-
bance at 410 nm (±SD) of 35 SLE sera binding to 
native and ROS-damaged IgG was 0.51 ± 0.10 and 
1.3 ± 0.11, respectively. Whereas, 39 NHS binding to 
native and ROS-human IgG antigens was 0.19 ± 0.12 
and 0.22 ± 0.10, respectively. Table 3 summaries the 
complete immunological studies of study subjects.Al-Shobaili et al
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The  binding  specificity  of  antibodies  from 
35 selected SLE sera was evaluated by competition 
ELISA using native and ROS-modified IgG as inhib-
itors.  Mircrotitre  plates  were  coated  with  human 
DNA. Figure 2 illustrates inhibition of SLE autoan-
tibodies (in sera 1 to 6) binding to native DNA by 
native or ROS-modified IgG.   Microtiter plates were 
coated with native DNA. Our data showed strong 
reactivity of autoantibodies in patient’s sera towards 
ROS-IgG over native IgG (P , 0.01). Similarly, the 
rest of the sera showed high percent inhibitions with 
modified IgG over native IgG (data summarized in 
Table 3). The average percent inhibition (±SD) in 
the binding of 35 SLE sera to ROS-modified and 
unmodified  IgG  was  54.4  ±  8.2  and  27.8  ±  7.9, 
respectively. The data reveals striking differences 
in the recognition of native and oxidized IgG by 
SLE autoantibodies (P , 0.001) (Table 3).
Elevated  level  of  protein  carbonyl  contents  in 
the serum is considered to be the most reliable bio-
marker of oxidative stress. The data showed signifi-
cantly increase in serum protein carbonyl contents 
(P , 0.05) in SLE patients, compared with normal 
subjects of the same age group. The average carbo-
nyl contents (±SD) of 12 independent assays of SLE 
serum proteins and normal human serum (NHS) pro-
teins were 3.9 ± 0.42 and 2.4 ± 0.21 nmol/mg protein, 
respectively (Table 3). A P-value of ,0.01 indicates 
significant  difference  in  the  carbonyl  contents  of 
SLE-serum and NH-serum.
Discussion
Reactive oxygen species (ROS) play a key role in both 
normal biological functions and in the pathogenesis 
of certain human diseases. These species are continu-
ously generated in cells by cellular metabolism and by 
exogenous agents but increase in their steady states 
are thought to be responsible for a variety of patholog-
ical conditions, including SLE, cancer and aging.7,22,37 
ROS  in  excessive  amount  have  the    ability,  either 
directly or indirectly, to damage proteins, DNA and 
other cell biomolecules.7–22 Among the ROS, hydroxyl 
radicals are the most potent damaging ROS which can 
react with almost all biological macromolecules.15–21 
Proteins are the major targets for free radical attack 
mainly  by  hydroxyl  radicals.17  Protein  oxidation, 
results in cellular dysfunctions, functional disruption 
and structural changes and contributes to the etiology 
of many human diseases.9,11–14 These oxidative modifi-
cations on protein may lead to the formation of neoan-
tigens which could in turn initiate autoimmunity.
Table 3. Immunological details of study subjects.
Parameters SLE-serum NH-serum
Age 47.4 ± 15.3 (n = 35) 45.7 ± 13.8 (n = 39)
Sex 33F/2M 36F/3M
Detection of anti-rOS-human  
Igg antibodies
A410 (rOS-Igg) 1.3 ± 0.11* 0.22 ± 0.10
MPI (rOS-Igg) 54.4 ± 8.2** 13.3 ± 5.7
Detection of anti-human A410 (n-Igg) 0.51 ± 0.10 0.19 ± 0.12
Igg antibodies  MPI (n-Igg) 27.8 ± 7.9 12.9 ± 8.2
Carbonyl contents  3.9 ± 0.42#  2.4 ± 0.21 
(nmol/mg protein) (n = 12) (n = 12)
Note: *P , 0.01 vs. A410 (n-Igg); **P , 0.01 vs. MPI (n-Igg); #P , 0.05 vs. carbonyl content (nh-serum).
Abbreviations: SLe-serum, serum from systemic lupus erythematosus patients; nh-serum, serum from normal human; n, number of samples tested; 
F, females; M, males; n-Igg, native Igg; A410, absorbance at 410 nm calculated by direct binding eLISA; MPI, maximum percent inhibition at 20 µg/ml of 
inhibitor concentration calculated by competitive inhibition eLISA.
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Figure 1. Direct binding eLISA of 1:100 diluted SLe and normal human 
serum samples. The microtitre plates were individually coated with native 
DnA (2.5 µg/ml), native and ROS-modified IgG (5 µg/ml). The number 
of SLe serum samples was 35 and nh serum samples were 39. Data 
presented as mean ± SEM of five independent assays; data without a 
common letter differ, P , 0.05.rOS-Igg in SLe
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It  is  well  established  that  IgG  is  an  abundant 
protein  in  the  circulatory  system,  whose  redox 
modifications  modulate  its  physiologic  functions,23 
as  well  as  may  serve  as  a  biomarker  of  oxidative 
stress.23–25,27–29 IgG is continuously exposed to oxida-
tive stress23–25 bringing about alterations in conforma-
tion and functions of IgG, resulting in modification of 
its biological   properties. We previously demonstrated 
that ROS caused extensive damaged to human IgG 
and damaged IgG was found to be a potent antigenic 
stimulus  inducing  high  titre  antibodies  in  rabbits, 
whereas with native human IgG, antibodies titre was 
low.20  The  antigenic  specificity  of  affinity  purified 
anti-ROS-human IgG and anti-native IgG antibodies 
reiterated that induced antibodies were immunogen 
specific. The substantially enhanced immunogenicity 
of ROS-human IgG in comparison to native analogue 
could possibly be due to the generation of potential 
neo-epitopes against which antibodies are raised.
In the present study, we demonstrated for the very 
first  time  that  experimentally  induced  antibodies 
against ROS-damaged human IgG exhibited diverse 
antigen binding characteristics. Native DNA, native 
chromatin, and their ROS-  modified conformers were 
found to be effective inhibitors of induced antibody-
immunogen   interaction. Whereas, induced   antibodies 
against  native  IgG  showed    negligible    binding  to 
the above mentioned nucleic acid conformers. This 
notable feature of induced antibodies against ROS-
modified IgG resembled the diverse antigen-binding 
characteristics of naturally occurring SLE anti-DNA 
autoantibodies.
SLE  is  a  chronic  autoimmune  disease  that  is 
characterized  by  increased  production  of  autoan-
tibodies,  but  the  initial  immunizing  antigens  that 
drive the development of SLE are largely unknown. 
  Autoantibody  production  in  SLE  has  been  attrib-
uted  to  either  selective  stimulation  of  autoreactive 
B  cells  by  self  antigens  or  antigens  cross-reactive 
with self.1,2,7 Numerous modified forms of DNA have 
been found to be immunogenic and are recognized by 
SLE anti-DNA antibodies.7,31,38 Despite the power of 
modern molecular approaches and persistent investi-
gative efforts, lupus remains an enigmatic disorder6 
and the agent (or agents) triggering this autoimmune 
response remains to be identified. Patients with SLE 
have a diverse array of anti-nuclear autoantibodies, 
but the cellular and molecular mechanisms that are 
responsible for the production of anti-nuclear anti-
bodies in SLE and the way by which these antibodies 
participate in tissue destruction remain highly contro-
versial.39 It was thought worthwhile to investigate the 
binding characteristics of natural SLE   autoantibodies 
to  ROS-damaged  human  IgG  as  that  the  possible 
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Figure 2. Competitive inhibition ELISA of SLE serum antibody from six patients (1 to 6). The inhibitors used were native human IgG and ROS-modified 
human Igg. The microtitre plates were coated with the native DnA (2.5 µg/ml). Varying amounts of inhibitors (0.01–20 µg/ml) were allowed to interact with 
a constant amount of antiserum for 2 h and overnight at 4 °C, the mixture was added to antigen-coated plates and the residual antibody level was detected 
by eLISA. each histogram represents the mean ± SeM of three independent assays.Al-Shobaili et al
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involvement of ROS-modified IgG in SLE could be 
ascertained. Sera from 72 SLE patients having high 
titre anti-DNA antibodies and 39 normal human sub-
jects were collected for the present study. Of these, 
48.6%  SLE  sera  showed  preferentially  high  bind-
ing to ROS-IgG as compared to its native analogue 
(P , 0.01) as determined by direct binding ELISA 
assays.  Native  or  modified  IgG  showed  no  appre-
ciable binding with normal subjects (P . 0.05). We 
also noticed that unmodified IgG showed some bind-
ing to SLE serum antibodies as compared with the 
antibodies from NHS (P , 0.05), this may be due to 
the partial structural similarities of native and modi-
fied IgG, which may shared common paratope of SLE 
autoantibodies.  Competition  ELISA  assays  further 
confirmed the direct binding results. Our data clearly 
indicated that SLE autoantibodies showed substantial 
difference in the recognition of modified IgG over 
native IgG (P , 0.01).
The oxidation of a protein typically results in an 
increase in carbonyl contents. This increase is due to the 
oxidation of lys, arg, pro or other amino acid residues. 
In short, protein carbonyl groups are the biomarker of 
oxidative stress.35 In human plasma, all amino acids in 
the protein are susceptible to oxidative modification 
by oxidants such as hydroxyl radicals and hypochlo-
rous acid.35 In view of these, carbonyl contents present 
in the total serum protein of SLE were investigated. 
Our results showed that total serum protein carbonyl 
contents were significantly increased in SLE patients, 
when  compared  with  the  carbonyl  contents  pres-
ent in total serum protein of healthy human subjects 
(P , 0.05). These results indicated that in SLE patients 
with increased oxidative stress, the oxidative modifi-
cation of plasma proteins has been greatly enhanced. 
Since the abundant protein of plasma is IgG, it is likely 
to be extensively damaged and might be responsible 
for the pathological conditions associated with SLE. 
These results suggest that IgG is continuously exposed 
to oxidative stress, so much so that alterations in its 
biological properties could result in the conformational 
changes of IgG. Our results demonstrate the presence 
of ROS-induced human IgG damage in SLE patients, 
which might play an active part in the progression of 
disease. The present study further proposed that, in 
addition  to  IgG  in  serum  concentration,  the  quality 
of  IgG  molecules  may  be  not  only  a  crucial  factor 
  affecting its protective effects, but also a risk factor as 
a   pro-oxidant in SLE patients.
Conclusions
Ours is the first report to show the role of hydroxyl 
radical  damaged  immunoglobulin  G  in  SLE.  Our 
results provide new suggestions that hydroxyl radi-
cal modification of IgG causes perturbations, result-
ing in the generation of neo-epitopes, and making it a 
potential immunogen. The induced antibodies against 
hydroxyl radical-modified IgG resembled the diverse 
antigen-binding characteristics of naturally occurring 
SLE  anti-DNA  autoantibodies.  The  IgG  modified 
with the hydroxyl radicals may be one of the factors 
for the induction of circulating SLE autoantibodies.
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